Real-world data of key markets such as Germany is increasingly being used by pharmaceutical and medical device companies to bring insights in different domains: epidemiology, humanistic and economic disease burden, treatment patterns, patient characteristics, safety, comparative effectiveness, and others. In Germany, data originating from the statutory healthcare system provide undistorted insights into the German in-and outpatient care setting as well as the full picture due to the data linkage between both settings.
Claims data can be captured in different ways: representative or not representative. Therefore, it is important to understand the positive impact of using representative databases and also the consequences of using unrepresentative databases. This webinar aims to provide a detailed overview of the German healthcare system, and the unique use of representative statutory healthcare sickness funds data in real world research, providing real examples about how to use existing data to support decisions in the healthcare sector and to elucidate potential limitations in using such claims data also from a payer & regulator perspective.
- Structure of the German Healthcare System.
- German sickness funds claims data architecture.
- How to demonstrate representativeness of German Sickness Funds data – the Morbi-RSA approach.
- Opportunities & limitations in using German claims data for real world research – the IQWiG/G-BA perspective.
Who should attend:
- Employees of pharmaceutical and medical device companies: medical affairs, HEOR, epidemiologists, product leaders, marketing, etc.
- Academic and public employees involved in healthcare system planning and evaluation